Format

Send to

Choose Destination
J Pathol. 2017 Nov;243(3):366-375. doi: 10.1002/path.4955. Epub 2017 Sep 29.

Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study.

Author information

1
German Cancer Consortium (DKTK), Heidelberg, Germany.
2
Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
3
German Cancer Research Center (DKFZ), Heidelberg, Germany.
4
Institute of Molecular Medicine and Cell Research, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
5
Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
6
Department of Surgical Oncology, University Clinic Heidelberg, Heidelberg, Germany.
7
Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
8
Department of General Pathology, University Clinic Heidelberg, Heidelberg, Germany.
9
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
10
Lübeck Institute of Experimental Dermatology and Institute of Cardiogenetics, University of Lübeck, Lübeck, Germany.
11
Population Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, USA.
12
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA.

Abstract

Smoking tobacco is a known risk factor for the development of colorectal cancer and for mortality associated with the disease. Smoking has been reported to be associated with changes in DNA methylation in blood and in lung tumour tissues, although there has been scant investigation of how epigenetic factors may be implicated in the increased risk of developing colorectal cancer. To identify epigenetic changes associated with smoking behaviours, we performed epigenome-wide analysis of DNA methylation in colorectal tumours from 36 never-smokers, 47 former smokers, and 13 active smokers, and in adjacent mucosa from 49 never-smokers, 64 former smokers, and 18 active smokers. Our analyses identified 15 CpG sites within the APC 1A promoter that were significantly hypermethylated and 14 CpG loci within the NFATC1 gene body that were significantly hypomethylated (pLIS < 1 × 10-5 ) in the tumours of active smokers. The APC 1A promoter was hypermethylated in 7 of 36 tumours from never-smokers (19%), 12 of 47 tumours from former smokers (26%), and 8 of 13 tumours from active smokers (62%). Promoter hypermethylation was positively associated with duration of smoking (Spearman rank correlation, ρ = 0.26, p = 0.03) and was confined to tumours, with hypermethylation never being observed in adjacent mucosa. Further analysis of adjacent mucosa revealed significant hypomethylation of four loci associated with the TNXB gene in tissue from active smokers. Our findings provide exploratory evidence for hypermethylation of the key tumour suppressor gene APC being implicated in smoking-associated colorectal carcinogenesis. Further work is required to establish the validity of our observations in independent cohorts. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

KEYWORDS:

APC; DNA methylation; colorectal cancer; epigenetics; smoking; tobacco

PMID:
28791728
PMCID:
PMC5647242
DOI:
10.1002/path.4955
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center